This company has been acquired
Provention Bio Crecimiento futuro
Future controles de criterios 5/6
Información clave
75.7%
Tasa de crecimiento de los beneficios
64.7%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 22.8% |
Tasa de crecimiento de los ingresos | 42.8% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 31 Mar 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Provention Bio appoints O'Brien as Chief People Officer
Sep 19Provention Bio secures $125M term loan facility
Sep 01Provention Bio: More Risk, More Dilution Ahead - Downgrading To A Sell Rating
Aug 12Provention Bio Q2 2022 Earnings Preview
Aug 03Provention Bio to raise $60M through private placement of securities
Jul 08Provention Bio says FDA extends review period for co's teplizumab application to Nov. 17
Jun 30Provention Bio (PRVB): BLA Accepted; Downgrading To A Hold
Mar 31Provention Bio: Upgrading To A Strong-Buy, Potential Cure For Type 1 Diabetes
Feb 04Is Provention Bio (NASDAQ:PRVB) In A Good Position To Invest In Growth?
Jan 11Is Provention Bio (NASDAQ:PRVB) In A Good Position To Deliver On Growth Plans?
Aug 26Provention Bio: Blood (Glucose) In The Streets
Jul 30FDA Advisory Committee supports Provention Bio's teplizumab in delaying diabetes
May 28Provention Bio EPS misses by $0.05
May 06Provention Bio provides regulatory update on teplizumab BLA
Apr 27How Much Of Provention Bio, Inc. (NASDAQ:PRVB) Do Insiders Own?
Mar 17Need To Know: Provention Bio, Inc. (NASDAQ:PRVB) Insiders Have Been Buying Shares
Feb 10Provention Bio prices $100M stock offering
Jan 14Provention Bio Could See Meaningful Upside Once Teplizumab Hits The Market
Jan 07Provention Bio (NASDAQ:PRVB) Is In A Good Position To Deliver On Growth Plans
Jan 06Provention Bio files US application for its diabetes drug
Jan 04Provention Bio launches first-in-human PRV-101 study in coxsackievirus B
Dec 15Is Provention Bio, Inc.'s (NASDAQ:PRVB) Shareholder Ownership Skewed Towards Insiders?
Dec 02Provention Bio EPS misses by $0.14
Nov 05Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2025 | 452 | 168 | 34 | 179 | 3 |
12/31/2024 | 180 | -13 | -134 | -78 | 4 |
12/31/2023 | 47 | -159 | -201 | -139 | 2 |
12/31/2022 | 13 | -114 | -76 | -75 | N/A |
9/30/2022 | 3 | -106 | -91 | -91 | N/A |
6/30/2022 | 3 | -105 | -93 | -92 | N/A |
3/31/2022 | 2 | -104 | -95 | -94 | N/A |
12/31/2021 | 1 | -114 | -96 | -95 | N/A |
9/30/2021 | 1 | -121 | -98 | -97 | N/A |
6/30/2021 | N/A | -125 | -98 | -96 | N/A |
3/31/2021 | N/A | -118 | -85 | -84 | N/A |
12/31/2020 | N/A | -99 | -77 | -76 | N/A |
9/30/2020 | N/A | -77 | -62 | -61 | N/A |
6/30/2020 | N/A | -55 | -46 | -46 | N/A |
3/31/2020 | N/A | -45 | -38 | -38 | N/A |
12/31/2019 | N/A | -43 | -36 | -36 | N/A |
9/30/2019 | N/A | -38 | -32 | -32 | N/A |
6/30/2019 | N/A | -34 | -29 | -29 | N/A |
3/31/2019 | N/A | -33 | -24 | -24 | N/A |
12/31/2018 | N/A | -27 | -23 | -23 | N/A |
9/30/2018 | N/A | -25 | -20 | -20 | N/A |
6/30/2018 | N/A | -21 | -15 | -15 | N/A |
3/31/2018 | N/A | -15 | -11 | -11 | N/A |
12/31/2017 | N/A | -9 | -5 | -5 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: PRVB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).
Beneficios vs. Mercado: PRVB is forecast to become profitable over the next 3 years, which is considered above average market growth.
Beneficios de alto crecimiento: PRVB is expected to become profitable in the next 3 years.
Ingresos vs. Mercado: PRVB's revenue (42.8% per year) is forecast to grow faster than the US market (7% per year).
Ingresos de alto crecimiento: PRVB's revenue (42.8% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if PRVB's Return on Equity is forecast to be high in 3 years time